Core Insights - Cormorant Asset Management sold its entire stake in Arcellx for an estimated $63.63 million, liquidating 775,000 shares as of February 17, 2026 [1][2] Company Overview - Arcellx's current stock price is $114.51, with a market capitalization of $6.7 billion and a revenue of $22.3 million over the trailing twelve months (TTM). The company reported a net income loss of $228.9 million TTM [4] - Arcellx is focused on developing proprietary ddCAR and ARC-T cell platforms to address unmet medical needs in relapsed or refractory cancers, with a pipeline that includes candidates for hematologic malignancies and solid tumors [5][8] Recent Developments - Arcellx shares have increased by 80% this year, driven by the development of next-generation CAR-T cell therapies, particularly anitocabtagene autoleucel, which has shown strong clinical responses [9] - A recent takeover agreement from Gilead Sciences values Arcellx at approximately $7.8 billion, offering shareholders $115 per share in cash, along with potential additional payments tied to future sales milestones [10] Investment Implications - Following the sale, Cormorant's position in Arcellx dropped from 4.4% of its 13F reportable assets under management (AUM) to zero. The fund's top holdings now include NASDAQ:PRAX at $280 million (15.9% of AUM) and NASDAQ:BBOT at $223.84 million (12.7% of AUM) [7] - Arcellx's stock performance has significantly outpaced the S&P 500, which gained approximately 19% over the same period [7]

Core Insights - Gilead Sciences, Inc. (GILD) is facing competitive pressures in its cell therapy franchise, which includes Yescarta and Tecartus, leading to a 7% year-over-year sales decline to $1.8 billion in 2025 [1][9] - To address this decline, GILD plans to acquire Arcellx for $7.8 billion, which will enhance its control over the anito-cel therapy and streamline development and commercialization [2][4][9] Sales Performance - Sales from GILD's cell therapy unit decreased by 7% year-over-year to $1.8 billion in 2025, with Yescarta sales down 5% to $1.5 billion and Tecartus sales down 15% to $344 million [1][9] - The decline is attributed to increasing competition from both in-class and out-of-class therapies [1][9] Acquisition Strategy - GILD's acquisition of Arcellx is valued at $115 per share in cash plus a $5 contingent value right, totaling an equity value of $7.8 billion [2] - This acquisition will provide GILD full control over anito-cel, eliminating profit-sharing and enhancing long-term margin potential [4] Pipeline Developments - GILD's subsidiary, Kite, is collaborating with Arcellx to co-develop anito-cel, which has received FDA acceptance for a biologics license application as a treatment for relapsed or refractory multiple myeloma, with a decision expected in December 2026 [3][4] Competitive Landscape - GILD faces strong competition in the cell therapy market from companies like Bristol Myers (BMY) and Novartis (NVS), with BMY's Breyanzi surpassing $1 billion in annualized sales in 2025 [6][7] - NVS's Kymriah recorded sales of $381 million in 2025, reflecting a 14% decline due to competitive pressures [8] Financial Performance - GILD's shares have increased by 30.3% over the past year, outperforming the industry growth of 15.4% [11] - The current price/earnings ratio for GILD is 16.41x forward earnings, higher than its historical mean of 11.32x but lower than the large-cap pharma industry average of 17.89x [13] Earnings Estimates - The bottom-line estimate for GILD in 2026 has increased to $8.66 from $8.60, while the estimate for 2027 has risen to $9.63 from $9.33 [14]

Group 1 - Gilead Sciences announced the acquisition of Arcellx, Inc. for up to $7.8 billion, paying $115 per share, which represents a 79% premium over Arcellx's last closing price [2] - Following the announcement, Arcellx's stock price surged by 77.9% to $114.06 in morning trading [2] - This acquisition is Gilead's largest since its $21 billion purchase of Immunomedics in 2020, as the company seeks to diversify beyond its traditional HIV and liver disease therapies [2][3] Group 2 - The acquisition enhances Gilead's position in cell therapy, particularly with an investigational CAR-T treatment for multiple myeloma, which is under FDA consideration as a fourth-line treatment [3] - Gilead expects the transaction to be finalized in the second quarter of 2026 [3] - Analysts suggest that the new treatment may have a better safety profile compared to existing therapies, indicating potential competitive advantages in the market [3]

Group 1 - As of March 4, 2026, two stocks in the health care sector are signaling potential warnings for momentum-focused investors [1] - The Relative Strength Index (RSI) is highlighted as a key momentum indicator, with a threshold of 70 indicating overbought conditions [2] - Anika Therapeutics Inc (NASDAQ:ANIK) and Arcellx Inc (NASDAQ:ACLX) are identified as major overbought stocks in the health care sector [3]

Core Insights - Two stocks in the health care sector are signaling potential warnings for momentum-focused investors as of March 4, 2026 [1] Group 1: Momentum Indicators - The Relative Strength Index (RSI) is a key momentum indicator that compares a stock's performance on days with price increases to days with price decreases [2] - An asset is generally considered overbought when the RSI exceeds 70, indicating potential caution for traders [2] Group 2: Overbought Stocks - Anika Therapeutics Inc (NASDAQ:ANIK) is identified as one of the major overbought stocks in the health care sector [3] - Arcellx Inc (NASDAQ:ACLX) is also listed among the overbought players in this sector [3]

Core Insights - Baron is an asset management firm that specializes in growth equity investment solutions, emphasizing a long-term and fundamental approach to growth investing [1] - Founded in 1982, Baron has established a reputation for its active investment strategies, with research being a central component of its operations [1] Company Overview - Baron was originally founded as an equity research firm, which highlights the importance of research in its business model [1] - The firm has evolved over the years but continues to focus on delivering growth equity investment solutions [1]

Core Viewpoint - Baron is an asset management firm that specializes in growth equity investment solutions, emphasizing a long-term and fundamental approach to growth investing [1] Company Overview - Founded in 1982, Baron has established a reputation for its active investment strategies focused on growth [1] - The firm originated as an equity research company, and research continues to be a fundamental aspect of its operations [1] Communication Note - The account mentioned is not managed or monitored by Baron Capital, and inquiries should be directed through official channels [1]

Core Viewpoint - AST SpaceMobile, Inc. reported mixed fourth-quarter earnings, with a larger-than-expected loss but significantly higher revenue than anticipated, leading to an increase in stock price. Group 1: Fourth-Quarter Results - The company reported a loss of 26 cents per share, missing the consensus estimate of a 15 cent loss [2] - Revenue for the quarter was $54.30 million, surpassing the consensus estimate of $41.10 million [2] - AST SpaceMobile has secured over $1.2 billion in aggregate contracted revenue commitments from commercial partners and reported $2.8 billion in cash, cash equivalents, and restricted cash as of December 31 [2] Group 2: Satellite Deployment and Future Plans - AST SpaceMobile continues its satellite deployment campaign, aiming for 45 to 60 satellites in orbit by the end of 2026 [3] - The company became a revenue-generating business in 2025 and made significant advancements in various operational aspects, including commercial, government, manufacturing, spectrum rights, IP portfolio, and capital position [3] - In 2026, the company expects to scale its space-based direct-to-device network from initial commercial activation toward broader commercial service [4] Group 3: Stock Performance - AST shares are trading 4.23% higher at $90.60 at the time of publication [4]

Core Insights - Rami Elghandour, President of Arcellx, sold 89,916 shares for approximately $10.24 million on February 27, 2026, as per SEC Form 4 filing [1][2] - The company is set to be acquired by Gilead Sciences for an estimated $7.8 billion, with Gilead purchasing Arcellx at $115 per share and a contingent value right of $5 per share [6] - Arcellx has made significant advancements in its clinical-stage projects, including a multiple myeloma treatment progressing to Phase 2 development and a blood cancer immunotherapy awaiting FDA approval [7] Transaction Summary - Shares sold (direct): 89,916 [2] - Transaction value: $10.2 million [2] - Post-transaction shares (direct): 276,051 [2] - Post-transaction shares (indirect): 416,500 [2] - Post-transaction value (direct ownership): approximately $31.41 million [2] Company Overview - Current stock price: $113.79 [4] - Market capitalization: $6.65 billion [4] - Net loss (TTM): -$228.93 million [4] - 1-year price change: 75.55% [4] Company Snapshot - Arcellx, Inc. is a clinical-stage biotechnology company focused on innovative immunotherapies for cancer and other incurable diseases, primarily working with oncology healthcare providers and patients in the U.S. and select global markets [5] Insider Activity - Elghandour's recent sale of 89,916 shares is significantly larger than his historical median sell size of 38,300 shares since January 2025 [8] - After the sale, Elghandour retains 276,051 shares in direct ownership and maintains 416,500 shares indirectly through a spousal trust, indicating continued material exposure to Arcellx equity [8] Future Prospects - If the treatment for multiple myeloma proves successful, it could become a major product in the healthcare space and a significant revenue generator for Arcellx [9] - The impending merger raises questions about the timeline for investors to trade shares before the company is delisted [9]

Core Insights - Rami Elghandour, President of Arcellx, sold 89,916 shares for approximately $10.24 million on February 27, 2026, as per SEC Form 4 filing [1][2] - The company is set to be acquired by Gilead Sciences for an estimated $7.8 billion, with a purchase price of $115 per share and a contingent value right of $5 per share [6] - Arcellx has made significant advancements in its clinical-stage projects, including a multiple myeloma treatment progressing to Phase 2 development and a blood cancer immunotherapy awaiting FDA approval [7] Transaction Summary - Shares sold (direct): 89,916 [2] - Transaction value: $10.2 million [2] - Post-transaction shares (direct): 276,051 [2] - Post-transaction shares (indirect): 416,500 [2] - Post-transaction value (direct ownership): approximately $31.41 million [2] Company Overview - Current stock price: $113.79 [4] - Market capitalization: $6.65 billion [4] - Net loss (TTM): -$228.93 million [4] - 1-year price change: 75.55% [4] Company Snapshot - Arcellx, Inc. is a clinical-stage biotechnology company focused on innovative immunotherapies for cancer and other incurable diseases, primarily working with oncology healthcare providers and patients in the U.S. and select global markets [5] Insider Activity - The recent sale of 89,916 shares is significantly larger than Elghandour's historical median sell size of 38,300 shares since January 2025 [8] - Post-sale, Elghandour retains 276,051 shares in direct ownership and maintains 416,500 shares indirectly through a spousal trust, indicating continued material exposure to Arcellx equity [8] Future Prospects - If the treatment for multiple myeloma proves successful, it could become a major product in the healthcare space and a significant revenue generator for Arcellx [9] - The impending merger raises questions about the timeline for trading shares before the company is delisted [9]